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DNA  non-homologous  end-joining  (NHEJ)  is the  major  DNA  double  strand  break  (DSB)  repair  pathway  in
mammalian  cells.  Defects  in  NHEJ  proteins  confer  marked  radiosensitivity  in cell lines  and  mice  models,
since  radiation  potently  induces  DSBs.  The  process  of  V(D)J  recombination  functions  during  the  devel-
opment  of  the  immune  response,  and  involves  the  introduction  and  rejoining  of programmed  DSBs  to
generate  an array  of  diverse  T  and  B cells.  NHEJ  rejoins  these  programmed  DSBs.  Consequently,  NHEJ
deﬁciency  confers  (severe)  combined  immunodeﬁciency  – (S)CID  – due  to a  failure  to  carry  out V(D)J
recombination  efﬁciently.  NHEJ  also  functions  in class  switch  recombination,  another  step  enhancing  T
and  B  cell  diversity.  Prompted  by  these  ﬁndings,  a search  for radiosensitivity  amongst  (S)CID  patients
revealed  a radiosensitive  sub-class,  deﬁned  as  RS-SCID.  Mutations  in  NHEJ  genes,  deﬁning  human  syn-
dromes  deﬁcient  in  DNA  ligase  IV  (LIG4  Syndrome),  XLF-Cernunnos,  Artemis  or DNA-PKcs,  have been
identiﬁed  in such  patients.  Mutations  in  XRCC4  or Ku70,80  in  patients  have  not  been  identiﬁed.  RS-SCID
patients  frequently  display  additional  characteristics  including  microcephaly,  dysmorphic  facial  features
and  growth  delay.  Here,  we  overview  the  clinical  spectrum  of  RS-SCID  patients  and  discuss  our current
understanding  of  the  underlying  biology.
©  2014  Elsevier  B.V.  All  rights  reserved.. Introduction
A DNA double strand break (DSB) is a critical lesion promoting
ell death if unrepaired or genomic rearrangements if misrepaired.
hile ionising radiation (IR) is renowned for its avid ability to
nduce DSBs, around 10–20 DSBs arise endogenously per cell
er day. Perhaps surprisingly, cells also create DSBs, termed
rogrammed DSBs, during developmental processes such as
mmune development and meiosis. Signiﬁcantly, while the goal of
SB repair in somatic cells is to maintain genomic integrity and
tability, the end-point of the developmental processes involv-
ng programmed DSB formation is to create genetic diversity.
mazingly despite this basic difference, the same DSB pathway is
xploited to maintain genomic stability in the face of DNA damage
nduced DSBs and to create diversity during immune development,
DOI of original article: http://dx.doi.org/10.1016/j.dnarep.2014.02.011.
 This article is a reprint of a previously published article. For citation purposes,
lease  use the original publication details “DNA Repair 16 (2014) 84–96”.
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ttp://dx.doi.org/10.1016/j.dnarep.2014.04.002
568-7864/© 2014 Elsevier B.V. All rights reserved.although the underlying processes encompass tweaks to achieve
the distinct goals. The major DSB repair pathway in mammalian
cells is DNA non-homologous end-joining (NHEJ). Homologous
recombination (HR) also functions to rejoin DSBs but is limited to
situations where a sister chromatid, which serves as the source
of the homologous sequence, is present. HR, in fact, has a more
signiﬁcant role in promoting recovery from replication fork stalling
or collapse, a process which may  not involve DSB formation at all
or possibly a DSB with one end. HR also functions during meiosis,
which represents another situation when a sister chromosome is
present. The goal of this review is to focus on the clinical manifes-
tation of defects in NHEJ in patients. Since NHEJ functions during
immune development, we  will focus on the immunodeﬁciency
observed in NHEJ-defective patients. However, NHEJ deﬁciency
can also confer additional developmental abnormalities, including
microcephaly. We  aim to couple our current understanding of the
underlying biology with the clinical manifestation. We  will focus
on the impact in patients but call upon studies using cultured
cells and mouse models, as well as biochemical and structural
biology approaches to provide additional insight. Since most (but
not all) of the NHEJ proteins are essential for embryonic viabil-
ity, the mutational changes observed in patients are frequently
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ypomorphic (they are not fully inactivating and allow residual
rotein function). We  use the standard convention and describe
uch patients as being deﬁcient in the protein; complete loss of
rotein function (caused by a null mutational change) results in a
atient defective for the protein under discussion.
. The process of NHEJ
Current  insight into the NHEJ mechanism will be covered else-
here in this DNA Repair Special Issue. Other detailed reviews are
lso available [1–3]. Here, we provide only a brief overview encom-
assing points relevant for considering NHEJ-deﬁcient patients.
HEJ is initiated by binding of the Ku heterodimer to double
tranded (ds) DNA ends (Fig. 1). The rapid end-binding of Ku, which
rises in part from its avid capacity to bind DNA ends coupled with
ts high abundancy, provides prompt protection of the DNA ends
rom unwanted nucleolytic degradation; Ku end-binding addition-
lly recruits the DNA-PK catalytic subunit (DNA-PKcs) generating
he DNA-PK complex. DNA-PK is a phosphatidylinositol 3-kinase
PI3K)-like kinase with a kinase domain in the C-terminus [4].
tudies in vitro have demonstrated that Ku has the capacity to
ranslocate inwards forming multimeric complexes on the DNA
olecule [5]. There is, however, no evidence that this occurs in vivo
ig. 1. Process of NHEJ. Ku (shown as a 70/80 heterodimer in yellow/red), which
as  avid DNA end-binding activity and is highly abundant in human cells, rapidly
inds  DNA ends. DNA-bound Ku recruits DNA-PKcs, which activates DNA-PK activ-
ty. DNA-PK undergoes autophosphorylation at speciﬁc clusters of sites. DNA-PK
romotes  steps of end-processing, which can be carried out by PNKP and, for some
SBs, by the nuclease, Artemis. DNA-PK recruits the ligation complex, encompassing
NA  ligase IV, XRCC4 and XLF, which carries out the ﬁnal rejoining step.pair 17 (2014) 9–20
and indeed, exploitation of a recent novel approach for high res-
olution analysis of DNA bound proteins, has demonstrated that
in vivo only a single Ku molecule is present at each DNA end (i.e.
two molecules at a dsDNA end) [6]. However, DNA-PKcs recruit-
ment may  promote inward movement of the single Ku molecule,
which may  facilitate steps of end-processing. Assembly of DNA-
PK on DNA ends activates its kinase activity [7]. Structural studies
have shown that Ku is a basket shaped structure with a central core
of appropriate dimensions to allow its looping onto ds DNA with-
out necessitating interaction with nucleotide bases [8]. Ku-DNA
binding is, therefore, DNA sequence independent. The structure
of DNA-PKcs has revealed a ﬂexible ring shaped molecule arising
from multiple alpha-helical HEAT repeats (helix-turn-helix motifs),
which facilitate bending [9]. The ﬂexible structure and an opening
in the ring endows DNA-PKcs with the capacity to fold onto the DNA
molecule [10]. It is at this stage of the process that DNA-PK facili-
tates end-processing steps, which may  involve deletion formation
or “ﬁll in” regions of ssDNA regions [11]. Ligation requires 3′OH  and
5′P ends, which rarely arise following DNA damage, but are gen-
erated by a process involving polynucleotide kinase/phosphatase
(PNKP). DNA-PK may  promote PNKP processing by phosphory-
lation [12]. End-processing may  also require nuclease activities.
DNA-PKcs interacts with the structure speciﬁc nuclease, Artemis
[13]. Artemis has a Metallo--lactamase domain at its extreme
N-terminus and a closely localised -Casp domain [14]. The C-
terminus appears to be regulatory. Artemis, in contrast to other
NHEJ proteins, appears to be uniquely required for the repair of a
15% subset of DSBs, representing those repaired with slow kinet-
ics [15]. Moreover this process has an essential requirement for
DNA-PKcs [15]. Artemis also functions to open the hairpin ended
intermediates that form during the process of V(D)J recombina-
tion in a DNA-PKcs dependent manner (see further details below)
[13]. In G2 phase, where HR can also function, Artemis is, as in G1
phase, required for the slow component of DSB repair – however,
in G2 this slow repair process represents HR [16]. The available
evidence suggests that in G2 phase, there is a deﬁned switch from
rejoining by NHEJ to the use of HR in those situations where rapid
repair by NHEJ fails to ensue [17]. Thus, we propose a model in
which NHEJ initially attempts to repair all DSBs by a “core” pro-
cess that does not require Artemis processing but if this process
stalls, then a switch to promoting resection and repair by HR occurs
[17]. In contrast, Artemis is dispensable for HR following replica-
tion fork stalling/collapse. However, although Artemis is required
for resection, it does not appear to be the nuclease that directly
effects resection since it has the wrong polarity. We propose that
in G1 phase, a similar hierarchy exists. However, in G1  phase, the
slow rejoining process may  represent a form of resection-mediated
end-joining, such as microhomology mediated end-joining (MMEJ)
rather than HR, with resection being less extensive (Lobrich and
Jeggo laboratories, unpublished ﬁndings). The role of Artemis dur-
ing V(D)J recombination, where a hairpin end is the barrier to core
NHEJ-dependent rejoining, may  reﬂect a similar hierarchy with a
function for Artemis in opening the hairpin end [13]. It has been
proposed that, at least during V(D)J recombination, DNA-PKcs facil-
itates Artemis activity by remodelling the DNA end [18]. Whether
DNA-PKcs promotes Artemis function at damage-induced DSBs
remains to be determined. These in vivo roles of Artemis are con-
sistent with biochemical analysis showing that in the presence of
DNA-PK Artemis can cleave hairpin ends and 5′ and 3′ overhangs
[13,14].
Finally, DNA-PK plays an important role in recruiting the NHEJ
ligation complex, which encompasses XRCC4, DNA ligase IV and
XLF [19]. Recent studies also suggest that the ligation complex
may promote DNA-PKcs autophosphorylation, and potentially the
release of DNA-PK from the end [20]. Nonetheless, it is currently
unclear when removal of the DNA-PK complex occurs and whether
NA Repair 17 (2014) 9–20 11
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Fig. 2. Utilisation of NHEJ during V(D)J recombination. V, D and J segments are
sequentially  organised in genomic DNA and undergo rearrangement in T and B cells
during V(D)J recombination. The process is initiated by site speciﬁc DSBs introduced
by  the RAG1/2 recombinases directed by the RSS sequences. The coding ends form as
hairpins whilst the (signal) RSS ends are blunt ended. The DNA-PK complex assem-
bles at both the hairpin and blunt ends in a similar manner to the process shown in
Fig. 1. The signal ends are rejoined by simple NHEJ without requirement for Artemis.
In contrast, Artemis is required to cleave the hairpins arising at the coding ends.L. Woodbine et al. / D
t precedes or follows ligation. DNA-PK autophosphorylation has
een proposed as a mechanism promoting the assembly and dis-
ssembly of the DNA-PK complex on the DNA end [21]. However,
t least from in vitro studies, Ku remains attached to the DNA
nd [10]. If ligation occurs prior to loss of Ku, then there must be
egradation of Ku since its structure does not allow its release from
n intact DNA molecule [8]. RNF-8-dependent ubiquitylation has
een proposed as a potential mechanism regulating the removal
f Ku following DSB rejoining [22].
DNA ligase IV has a conserved ligase domain located at its N-
erminus, which can be subdivided into a DNA-binding and an
denylation domain [23,24]. A tandem BRCA1 C-terminus (BRCT)
omain is located in the C-terminus of DNA ligase IV. XRCC4 is a
omodimer and binds a single DNA ligase IV molecule [25]. XRCC4
as a globular head domain and helical tails that form a coiled coil
hat unwinds upon ligase binding. The region between the two
RCT motifs of DNA ligase IV and part of the second BRCT motif are
equired for binding to XRCC4 [25,26]. DNA ligase IV and XRCC4
nteract tightly and regulate one another’s stability [27–29]. XLF,
n contrast, is a weaker binding component of the ligation com-
lex [30]. XLF is structurally related to XRCC4 but crucially has a
horter coiled coil domain and undergoes a reverse in direction,
recluding the critical “kink” in the coiled coil that is required for
nteraction with DNA ligase IV [31,32]. Several recent studies have
roposed that XRCC4 and XLF form a protein ﬁlament along the
NA, that serves to bridge the DNA ends, suggesting a role in synap-
is [33–35]. Further, studies, however, are required to verify that
uch structures form in vivo.
. The exploitation of NHEJ during the development of the
mmune  response
While  the evolutionary pressure on NHEJ in the repair of dam-
ge induced DSBs is to maintain genomic stability and avoid
equence changes, the development of the immune response is
riven by the need to generate genetic diversity to produce a
road repertoire of different immunoglobulin and T cell receptor
enes that are able to recognise the wide array of distinct anti-
ens to which we are exposed. In germ line cells, the components
f the immunoglobulin and T cell receptor genes are sequentially
rranged as distinct arrays of variable (V), diversity (D) or joining
J) segments [36]. During immune development, the gene segments
ndergo rearrangement via the process of V(D)J recombination to
roduce distinct re-arrangements of V, D and J sub-fragments. The
rocess of V(D)J recombination has, like NHEJ, been described in
everal excellent reviews and only an outline will be given here
36–38]. In germ line cells, each V, D or J segment has a coding
egion, C, and a ﬂanking recombination signal sequence (RSS). V(D)J
ecombination is initiated by cleavage at each of two RSS sequences
y the RAG1/2 recombinases, thereby generating a synapsis com-
lex that encompasses two hairpin-ended and two blunt ended
SBs. The blunt ends form at the RSSs and rejoin by a process that
equires the core NHEJ proteins (Ku, DNA-PKcs, XRCC4, XLF and
NA ligase IV but not Artemis) to yield either circles or inversions
f the RSS sequences (Fig. 2). The ends of the coding sequences,
hich encode segments of the immunoglobulin and T cell recep-
or genes, arise as hairpins and require cleavage by Artemis prior to
ejoining by core NHEJ proteins. Following Artemis cleavage, which
oes not occur at the apex of the hairpin, nucleotide additions, ﬁll-
n or deletions can arise by processes involving terminal nucleotide
ransferase (TdT), and pol or  polymerases. These end modiﬁca-
ions add further to the diversity of the immunoglobulin and T cell
eceptor genes.
In  addition to V(D)J recombination, DSB formation also forms
uring immunoglobulin class switch recombination (CSR), anArtemis  cleaves non-apically and subsequent end processing involving nucleotide
insertions  by TdT, as well as potentially by Pol and pol helps to generate ends
with  deletions and/or insertions.
additional process that allows switching of immunoglobulin iso-
type subclasses. Since CSR necessitates that V(D)J recombination
has taken place, the more marked phenotype of mouse models
and human patients deﬁcient in NHEJ proteins is observed as
diminished V(D)J recombination. However, studies in animal
models in which a rearranged substrate is engineered into cells
has revealed the role for NHEJ proteins in CSR. Moreover, in mild
NHEJ-deﬁcient human phenotypes, a defect in CSR can be observed
and can present as markedly raised IgM, but diminished or absent
IgA and IgG. Here, however, we will focus on V(D)J recombination
given that reduced or absent T and B cells is the more common
phenotype observed in NHEJ deﬁcient patients.
4. The radiosensitive, severe combined immunodeﬁciency
(RS-SCID) phenotype
As  a consequence of the role of NHEJ in the rejoining of
radiation-induced DSBs and the programmed DSBs induced during
V(D)J recombination, patients deﬁcient in NHEJ proteins display
radiosensitivity and severe combined immunodeﬁciency (SCID),
a phenotype which has been called RS-SCID. To date, mutations
12 L. Woodbine et al. / DNA Repair 17 (2014) 9–20
Table  1
Clinical presentation and features of LIG4 Syndrome patients. All mutations are compound heterozygous unless speciﬁed as homozygous (H).
Patient Immune phenotype Developmental
delay/microcephaly
Cancers Mutation Reference
180BR No over immunodeﬁciency X/X Acute lymphoid
leukaemia
p.R278>HH [43]
CoDA  Mild immune deﬁciency X/X Squamous cell
carcinoma
p.R580X/p.R814X [104]
495BR  CID, neutropenia X/X X p.R278>P/p.E427>A [30]
P2  Neutropenia
√
/X X p.H282>L/p.D423X [105]
F07/614  CID X/
√
X p.A3>V/p.T9>I/p.R278>H Unpublished
P1  Neutropenia X/
√
X p.H282>L/p.D423X [105]
P1/P2  B and T cell lymphocytopenia X/
√
X p.Q280>R/p.K424FS [47]
411BR,
NBS2303,
NBS2304,
99P0149
Pancytopenia
Pancytopenia
Pancytopenia
Pancytopenia
√
/
√
√
/
√
√
/
√
√
/
√
B  cell lymphoma
X
X
X
p.A3>V/p.T9>I/p.R278>HH
p.R814X/p.R580X,
p.R814X/p.R580X,
p.R814X/p.G469>E
[39,100,50]
SC2  T-B-NK+ SCID X/X X p.Q433H [46]
P1  Progressive CID X/X EBV-non-Hodgkins
lymphoma
p.M249V/nucleotide position 1270–1274 [49]
P1  SCID with features of Omenn’s X/X  X p.H282LH [48]
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lines with homozygous changes at R278H, revealed that two  addi-
tional linked polymorphic changes in one patient correlated with a
more severe phenotype both clinically and at the cellular level [51].
Fig. 3. Location of mutational changes identiﬁed in LIGIV Syndrome patients. DNA
ligase IV cDNA has a ligase domain in its 5′ region, which includes a DNA bindingSyndrome
P1  Pancytopenia, hypo
gammaglobulinaemia
√
/
√
n four genes encoding components of the NHEJ machinery, LIG4
encoding DNA ligase IV), XLF (encoding XLF), PRKDC (encoding
NA-PKcs) and DCLRE1C/SNM3/Artemis encoding Artemis) have
een identiﬁed in patients (Figs. 3–6). Although RS-SCID represents
he extreme phenotype, radiosensitivity coupled with variable
mmunodeﬁciency ranging from Omenn’s Syndrome to CID or pan-
ytopaenia, or progressive immunodeﬁciency has been observed.
dditional features are also observed in some patients, including
icrocephaly and severe growth/developmental delay (Figs. 3–6).
he clinical manifestation arising from deﬁciency in each NHEJ
omponent will be described below and, where possible, consid-
red in the light of our knowledge of the protein’s structure and
ole in NHEJ.
.1.  LIG4 Syndrome
LIG4  Syndrome (OMIM606593), caused by mutations in DNA
igase IV, was the ﬁrst genetically deﬁned RS-CID disorder to be
escribed [39]. Disruption of the DNA ligase IV (Lig4) gene (result-
ng in complete loss of DNA ligase IV function) causes embryonic
ethality in mice with extensive neuronal apoptosis around E13.5
40–42]. Thus, DNA ligase IV is essential for embryonic viability.
onsequently, all mutations identiﬁed in patients are hypomor-
hic (i.e. not fully inactivating). The range of features observed in
atients and their mutational changes are given in Table 1; Fig. 3
verviews the sites of the mutational changes observed. The ﬁrst
atient mutated in Lig4 to be identiﬁed had no overt phenotype (i.e.
o obvious immunodeﬁciency) but developed acute lymphoblas-
ic leukaemia at age 14. The patient subsequently dramatically
ver-responded to cranial radiation treatment and died from radi-
tion morbidity [43,44]. This patient proved to have a homozygous
278H missense mutation which reduced DNA ligase IV activity
o ∼10% of the control level. Signiﬁcantly, the mutation is located
lose to the ATP binding site and is predicted to impede formation
f a DNA ligase IV-adenylate complex [45]. All subsequent patients
ave displayed more marked immunodeﬁciency although in most
ases low but residual T and B cells are present (i.e. a CID phenotype)
Table 1). However, some patients with a more pronounced SCID
henotype have been described and one patient displayed features
f Omenn’s Syndrome [46–48]. Microcephaly (a reduced head cir-
umference), growth delay and dysmorphic facial features are also
ommonly observed in patients (Table 1) [39]. Signiﬁcantly, micro-
ephaly is observed at birth but is not progressive post-natally.p.A797DfsX2/p.R814X Unpublished
Some  additional sporadic developmental anomalies have also been
described in some patients, such as bone abnormalities [39]. Lym-
phoid tumours have been observed in a small number of patients,
usually those with milder immunodeﬁciency, including the mild
patient described above who displayed no overt immunodeﬁciency
but developed leukaemia (Table 1) [44,49,50]. In all cases examined,
patient ﬁbroblasts show radiosensitivity and diminished DSB repair
capacity, which can be observed from early times post exposure
(Fig. 7). Since the mutations are hypomorphic, however, residual
DSB rejoining occurs with slow kinetics and normally by 24–72 h
post exposure all DSBs have been rejoined. Interestingly, from our
studies we have observed that the magnitude of DSB  capacity corre-
lates with the severity of clinical features. Thus, ﬁbroblasts derived
from the patient with the mildest features (i.e. no overt immuno-
deﬁciency or microcephaly) showed a greater DSB repair capacity
compared to ﬁbroblasts derived from patients with more severe
features [51]. Interestingly, in this context, an analysis of two celldomain  (DBD) and an adenylation domain. The 3′ region encompasses a tandem
BRCT  domain with a spacer region. The position of the mutations identiﬁed in
patients is shown. AV3 and T9I represent two closely linked polymorphic changes,
which  have been reported to impact upon DNA ligase IV activity but have been found
together with the R278H change in patients.
L. Woodbine et al. / DNA Repair 17 (2014) 9–20 13
Table  2
Clinical presentation and features of XLF-deﬁcient patients. All mutations are homozygous unless speciﬁed as compound heterozygous (CH). GR, growth delay; MCPH,
microcephaly; CID, combined immunodeﬁciency; SCID, severe combined immunodeﬁciency.
Patient Immune phenotype Developmental phenotype Mutation Reference
2BN SCID Small statue
MCPH
p.R178X [54]
P1
P2
P3
P4
P5
CID
CID
CID
CID
CID
GR/MCPH
GR/MCPH
GR/MCPH
GR/MCPH
GR/MCPH
p.R57G/p.C123RCH
p.R178X
p.G267
p.G267
p.R57G
[47]
[47]
[47]
[47]
[47]
P1 ? Polymicrogyria Chromosomal translocation
t(2;7)(q35;p22)
[106]
F07/402 SCID Developmental Delay/MCPH p.R57X [30]
P1
P2
P3
P4
P5
Immune deﬁciency
Mild  immune deﬁciency
?
Autoimmunity
?
MCPH
MCPH
MCPH
MCPH
p.R57G
c.495dupA/1.9kbCH
c.495dupA/1.9kbCH
p.R176X
p.R178X
[107]
[107]
[107]
[107]
[107]
P1 CID, macrocytic anaemia, GR/MCPH p.R57G [108]
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for a subset of DSB rejoining is not a unique feature of radiation-
induced DSBs, however, since a similar phenotype is observed
following exposure to oxidative damage or prolonged maintenance
of Artemis cells without subculturing where oxidative damage canneutropenia
P1 SCID GR
MCPH
The mutational changes identiﬁed in LIG4 Syndrome patients
re located throughout the gene and most changes are predicted
o impact upon function (Fig. 3). The point mutational changes
bserved are frequently localised within the adenylation domain,
ith structural analysis predicting an impact on adenylate complex
ormation [45]. Interestingly, although the severity of microcephaly
ormally correlates with the degree of immunodeﬁciency, one
atient with a pronounced SCID phenotype displayed no micro-
ephaly or growth delay providing evidence that these phenotypes
an be separated [46]. Further discussion of the basis underlying
icrocephaly in these patients is given in section 5 below.
.2.  XLF/Cernunnos defective patients
RS-SCID was described as a phenotype in a number of immuno-
eﬁciency patients but identifying the defective gene(s) progressed
lowly [52–54]. The identiﬁcation of mutations in DCLRE1C/Artemis
as the next genetic defect for RS-SCID to be identiﬁed, facilitated
y its occurrence within a community of Athabascan America Indi-
ns (see below for further details) [55]. Two distinct subsequent
pproaches led to the identiﬁcation of XLF (also called Cernunnos
r NHEJ1) as a further defect causal for RS-(S)CID (OMIM611291).
n one approach, a panel of cell lines from RS-(S)CID patients dis-
laying growth retardation, microcephaly, immunodeﬁciency and
ellular radiosensitivity was exploited to identify XLF/Cernunnos as
 cDNA able to complement the radiosensitivity phenotype [56]. A
econd approach centred on identifying proteins interacting with
NA ligase IV/XRCC4 revealed the same factor [31]. Signiﬁcantly,
LF proved to be the homologue of Nej1, another NHEJ factor that
as identiﬁed from studies in yeast [57–59]. Thus, XLF is addition-
lly called NHEJ1.
Microcephaly and growth delay is a feature observed in all XLF
atients (Table 2). In contrast to the situation with DNA ligase IV and
RCC4, disruption of XLF in mice does not appear to confer embry-
nic lethality, although XLF-defective mice display spontaneous
enomic instability and elevated translocations [60]. Although it
s difﬁcult to substantiate whether the mutational changes in
atients confer loss of function mutations, several XLF mutational
hanges do appear to fall into that category, with some represent-
ng severe truncating mutations [30]. The available data suggest
hat XLF may  not be essential for NHEJ although its loss profoundly
mpacts upon the process [30]. Despite the fact that XLF appears
o be non-essential for NHEJ whilst DNA ligase IV is essential,
linically XLF patients resemble the more severe LIG4 Syndromep.R178X [109]
patients  (compare Tables 1 and 2). Thus, inactivation of XLF con-
fers a clinical manifestation that is similar to partial loss of DNA
ligase IV. XLF-defective patient ﬁbroblasts also display a similar
level of radiosensitivity and magnitude of impaired DSB repair to
that observed in LIG4 Syndrome patients (Fig. 7). The mutational
changes identiﬁed in XLF patients are shown in Fig. 4.
4.3.  Artemis-defective patients
Loss of Artemis represents the most common cause of RS-SCID
(OMIM602450) [55]. This is likely because although Artemis has
an essential role in opening the hairpin intermediate during V(D)J
recombination, it does not appear to have any other essential devel-
opmental role and indeed knock-out mice are viable (see below for
further discussion) [61]. As discussed above, the role of Artemis in
NHEJ is distinct to other “core” NHEJ components, since Artemis
is essential for the rejoining of a ∼15% subset of radiation induced
DSBs [15]. Consequently, exposure of null-Artemis patient cells to
X or -Rays results in a fraction of DSBs remaining unrepaired for
prolonged periods (up to 21 days), which is distinct to the defect
observed in LIG4 Syndrome or XLF-defective patient cells, where
all DSBs are repair with slow kinetics (Fig. 7). Thus, by 1–7 days
post irradiation (3 Gy) all DSBs are rejoined in LIG4 Syndrome and
XLF-defective patient cells. This speciﬁc requirement of ArtemisFig. 4. Location of mutational changes identiﬁed in XLF-Cernunnos deﬁcient
patients.
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Fig. 5. Location of Mutations identiﬁed in Artemis in hypomorphic patients. Artemis
cDNA has a metallo- lactamase and a -CASP domain in its 5′ region and a regula-
tory  region, with phosphorylation sites at its 3′ end. The sites of mutations identiﬁed
in  hypomorphic mutations are shown. Note that some of these changes are likely to
The  presence of DSBs also initiates a signalling response,
which causes extensive changes to the chromatin in the DSB
Fig. 6. Mutations identiﬁed in DNA-PKcs in patients. Two  isoforms of DNA-PKcs
have  been described. The larger isoform (Isoform 1, Accession: NP 008835.5) is 4128
amino acids in length; the less common, smaller isoform (isoform 2) has a small dele-4 L. Woodbine et al. / D
ccumulate [62]. Similarly, Artemis is essential for cleaving the
airpin intermediate generated during V(D)J recombination but is
ispensable for the rejoining of the blunt-ended RSS ends [13]. Fur-
her discussion in the context of neuronal development is provided
elow.
.3.1. Clinical manifestation of hypomorphic mutations in
rtemis
A  substantial subset of Artemis patients have genomic deletions
hat result in loss of the transcriptional start site of Artemis cDNA;
ells from such patients display no detectable Artemis cDNA and
o detectable expression of Artemis protein [63]. Such Artemis
ull patients present with SCID, with an absence of T and B cells,
ecessitating bone marrow transplantation. It is notable that this
CID phenotype is more marked than most LIG4 or XLF-deﬁcient
atients, who show reduced but residual T and B cells (CID or
ancyotpaenia). Microcephaly, growth delay or dysmorphic facial
eatures have not been observed in Artemis null patients, although
rowth can be slow due to persistent infections and the consequent
ealth impact [55]. The classical Artemis null phenotype will not
e discussed in further detail here since this has been covered in
xcellent reviews [64,65].
Here, we will focus on reviewing a class of Artemis-deﬁcient
atients, termed “leaky” Artemis deﬁciency, whose importance is
ecoming increasingly recognised (Table 3) [66,67]. Perhaps unsur-
risingly, given that the level of residual Artemis expression may
over a range, the phenotype of such patients can be broad (Table 3).
nterestingly, such patients frequently display progressive immu-
odeﬁciency. One patient displayed Omenn’s Syndrome, due to
ligoclonal expansion of a reduced number of T or B cells [68]. Inter-
stingly, lymphomas, often EBV-associated, can be observed in such
atients, which is rarely seen in Artemis-null patients due to their
ack of B cells [55,69]. A similar phenotype is also observed in mouse
odels for Artemis deﬁciency [70,71]. This suggests that a small
umber of aberrant recombination events allow the expression of
ncogenes either directly or via an EBV-associated process. One
nteresting, late onset Artemis-deﬁcient patient with a homozy-
ous polymorphism in Artemis observed as a heterozygous change
n ∼1% of the Asian community displayed mild immunodeﬁciency
72]. The polymorphism was impacting on Artemis activity. Signif-
cantly, the patient developed progressive immunodeﬁciency and
on-lymphoid carcinomas. Since this was a single patient, however,
t is difﬁcult to assess the causal signiﬁcance. An important area of
uture work is to establish the contribution of Artemis-deﬁciency
o mild or progressive immunodeﬁciency, as well as to lymphoid as
ell as non-lymphoid cancers. The distribution of mutations found
n hypomorphic Artemis patients in shown in Fig. 5.
.4.  Defects in DNA-PKcs
Loss  of DNA-PKcs in mice confers SCID but no additional phe-
otype, similar to that observed following loss of Artemis [73,74].
hus, for many years it was an enigma that SCID or CID patients with
utations in DNA-PKcs had not been identiﬁed. In 2009 a DNA-PKcs
eﬁcient patient was reported with features closely resembling
hose of Artemis null patients (i.e. SCID without any other develop-
ental impact) [75]. Interestingly, the mutational changes did not
mpact upon DNA-PK kinase activity but rather on Artemis func-
ion. The fact that the mutational change had a subtle impact upon
NA-PK strengthened the emerging notion that DNA-PKcs may
ave a more signiﬁcant developmental function in humans com-
ared to mice [76]. This notion emerged from studies involving the
isruption of Ku or DNA-PKcs in human cell lines, representing a
ubstantial and important undertaking by the Henderson labora-
ory. Signiﬁcantly, these studies provided strong evidence that Ku
nd DNA-PKcs have roles in telomere maintenance in human cells,be inactivating changes (e.g. exon 1–3) since the hypomorphic change may  only
be in one allele. We have not distinguished the hypomorphic alleles since they has
not be identiﬁed in all cases.
which is not reﬂected in animal models; Ku is essential for viabil-
ity in human but not rodent cells and loss of DNA-PKcs, although
not essential, has a marked impact on proliferative capacity [77,78].
The available evidence suggested that the essential function may  lie
in telomere maintenance. More recently, another DNA-PKcs deﬁ-
cient patient with a dramatic neuronal phenotype was described
[79]. In this case, two heterozygous mutational changes resulted
in a marked impact on DNA-PK protein level and activity, with
only 1% of the normal DNA-PKcs being detectable and a very low
level of activity being observed in an assay for V(D)J recombination
(Fig. 6). The patient displayed marked microcephaly, developmen-
tal delay and, in contrast to LigIV Syndrome and XLF-deﬁcient
patients, neuronal degeneration was progressive post natally.
There was no evidence that the mutational changes conferred a
dominant negative phenotype, strongly suggesting that DNA-PK
has a major role during neuronal development (pre and post birth)
in humans but not in mice. Whilst it is possible that the underly-
ing cause of this phenotype is an inability to maintain telomere
length, the marked neuronal impact is not entirely consistent
with such an explanation. This will be discussed in more detail in
section 6.
5.  Related radiosensitive, immunodeﬁciency disorderstion in the C-terminal region (Accession: NP 001075109.1) and is 4097 amino acids
in length. DNA-PKcs cDNA has a P13K-like kinase domain in its extreme 3′ region
and  additional HEAT and FAT domains (only the FAT domains are shown). There are
two clusters of phosphorylation sites. Only two DNA-PKcs deﬁcient patients have
been identiﬁed and the mutational changes are shown.
L.
 W
oodbine
 et
 al.
 /
 D
N
A
 R
epair
 17
 (2014)
 9–20
 
15
Table 3
Clinical presentation and features of hypomorphic Artemis-deﬁcient patients. All mutations are compound heterozygous unless speciﬁed as homozygous(H).
Age at
onset
Failure
to
thrive
Recurrent
infections
Neutropenia Hyper IgM
syndrome
Autoimmunity Aneamia Lymphopenia Omenn’s
Syndrome
EBV-
associated
lymphoma
Carcinoma Mutation Artemis
expression and
V(D)J
recombination
Outcome Reference
Birth X
√
X X
√ √ √
X
√
X Exon 1-3/p.D451K Unknown Died of EBV
lymphoma
[69]
Birth X
√
X X X X
√
X
√
X Exon 1-3/p.D451K Low-level V(D)J Died of EBV
lymphoma
[69]
Birth X
√
X X
√ √ √
X X X Exon 1-3/p.T71P Unknown Successful
transplantation
[67]
5 mth
√
X  X X X X X
√
X X p.M1T/p.H35D Reduced
expression,
activity and
V(D)J
Successful
transplantation
[68]
6 mth  X
√
X X
√ √ √
X X X p.L70/p.G126D Reduced
expression,
normal V(D)J
Died of HSCT
complications
[110,111]
9 mth
√  √
X X X X
√
X X X c.464+1g>a/c.464+1g>aH Residual V(D)J Successful
transplantation
[112]
10 mth  X
√ √
X
√ √ √
X X X Exon 1-3/p.T71P Unknown Died of
aspergillosis
and  BMT
complications
[67]
1 yr X
√
X X X X
√
X X X Exon 1-3/p.D451K Low-level V(D)J Died of sepsis
and  respiratory
failure at 13
[69]
2 yr X X
√
X X X
√
X
√
X p.P171R/p.C436XH Reduced Successful
transplantation
[72]
4 yr X
√
X X X X
√
X X X p.E32ins61X/p.E32ins61X Reduced
expression,
defective V(D)J
Successful
transplantation
[113]
4 yr
√  √
X X X X
√
X X X p.T432SH Reduced V(D)J Died of liver
cirrhosis at 16
[69]
5  yr X
√
X X X X
√
X X X c.464+1g>a/c.464+1g>a Reduced
expression,
residual
activity,
defective V(D)J
Successful
transplantation
[113]
5 yr X
√
X
√
X X X X X X Exon 14 Unknown Died of septic
shock  at 6
[114]
27 yr X
√ √
X X X
√
X X
√
p.P171R/intronic
insertion= abnormal
splicing
Reduced
expression
On-going case [72]
? X X X X
√
X X X X X p.M1T/p.H35D Unknown Died of
aspergillosis
[68]
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Fig. 7. Distinct in DSB repair proﬁles by patient cells mutated in different NHEJ
proteins.  H2AX provides a sensitive procedure to monitor radiation induced DSB
formation and repair in G0 (serum starved) human ﬁbroblasts derived from patients
with mutations in the indicated genes. The results represent the analysis of a sin-
gle patient cell line but are reﬂective of the changes observed in multiple patients
(except  for DNA-PKcs, where only a single patient line is analysed). In control ﬁbro-
blast, DSB repair occurs with fast and slow kinetics. Cells deﬁcient in DNA ligase IV
or XRCC4 rejoin all their DSBs with slow kinetics (NB that the x-axis is not linear
so  the line drawn as linear loss of DSBs does not necessary reﬂect a linear process).
Cells  defective in Artemis, repair DSBs with the same kinetics as control cells up
to ∼6 h post irradiation, but fail to rejoin those DSBs repaired with slow kinetics in
control cells. The cell line deﬁcient in DNA-PKcs has a partial defective in the fast
c
r
v
a
a
n
c
p
o
O
R
B
a
i
a
o
T
o
p
r
e
o
i
e
a
m
s
e
[
m
d
m
t
f
d
M
a
elevation in numbers of unrepaired DSBs (<5). Whilst unrepairedomponent of DSB repair as well as a marked defect in the slow component. BG
epresents the background level of DSBs in the cells prior to radiation.
icinity and activates processes, such as cell cycle checkpoint
rrest, which inﬂuence but are not essential for NHEJ. The kinase,
taxia telangiectasia mutated (ATM), is central to the DSB sig-
alling response. Additionally, the MRE11/RAD50/NBS1 (MRN)
omplex is required for the ATM signalling response, at least in
art, due to a role in activating and recruiting ATM. Human dis-
rders defective or deﬁcient in ATM (ataxia telangiectasia; A-T;
MIM208900), MRE11 (AT-like disorder; ATLD; OMIM604391),
AD50 (RAD50 deﬁciency; OMIM613078) and NBS1 (Nijmegen
reakage Syndrome; NBS; OMIM251260) have been described
nd patients belonging to these disorders display radiosensitiv-
ty and variable levels of immunodeﬁciency [80–83]. Although,
 detailed description of these disorders falls outside the scope
f this review, they are brieﬂy discussed here for comparison.
he signalling response to DSBs has only a modest impact on the
verall level of DSB repair with ATM and the MRN  component
roteins only being essential for a subfraction (∼15%) of NHEJ,
epresenting those DSBs repaired with slow kinetics [15]. How-
ver, multiple studies have demonstrated a more qualitative effect
f these proteins on the ﬁdelity and/or efﬁciency of DSB rejoin-
ng [84]. A broader impact on the rejoining process is particularly
vident for the processes of V(D)J recombination and CSR, where,
lthough SCID is not a common feature of the disorders, a compro-
ised immune response is clearly evident in patients and multiple
tudies have demonstrated that loss of ATM or MRN  proteins inﬂu-
nces the nature, including the accuracy, of the V(D)J junctions
37,85,86].
A further distinct but overlapping impact lies in the develop-
ental features of the patients. Importantly, A-T and ATLD patients
isplay progressive ataxia and neurodegeneration but do not show
icrocephaly at birth like many of the NHEJ patients [84]. In con-
rast, NBS patients display microcephaly and dysmorphic facial
eatures like the NHEJ patients but not progressive ataxia [82]. This
istinction has been further confused by a recent description of
RE11-deﬁcient patients with features of NBS (i.e. microcephaly)
nd not progressive ataxia [87].pair 17 (2014) 9–20
6.  How does NHEJ deﬁciency confer microcephaly and
growth  delay
The  immunodeﬁciency conferred by defects in NHEJ is readily
explained by the well described role of NHEJ in rejoining the pro-
grammed DSBs introduced during both V(D)J recombination and
class switch recombination. The basis underlying the additional
developmental impacts of NHEJ deﬁciency is less clear, however.
The most frequent phenotypes are microcephaly and dysmorphic
facial features, with less commonly growth or developmental delay
being observed, and occasional additional features such as bone
abnormalities. Since most insight has been gained into the role of
NHEJ during neuronal embryogenesis, we will focus on that func-
tion. With the exception of the severe DNA-PKcs patient described
above, the microcephaly observed in most patients is evident at
birth but is not progressive. The study of mice knocked out for DNA
ligase IV and two hypomorphic mouse models for LIG4 Syndrome,
one of which involved the knock-in of a human mutational change
(R278H) observed in patients, have provided most insight into the
role of NHEJ during neurogenesis [40–42,88–90].
The embryonic neuronal stem and progenitor cells are located
in the ventricular and sub-ventricular zones (VZ-SVZ) which lie
adjacent to the ventricular membrane [91,92]. Adjacent to the
VZ-SVZ is the intermediate zone (IZ) with the cortical plate (CP)
representing a distal layer observed during later stages of neuroge-
nesis. The VZ-SVZ cells undergo extremely rapid cell division from
mouse developmental stage E8 to E16.5, after which cell division
ceases. Although there are stem/progenitor cells in the adult brain,
their rate of cell division is much reduced compared to this embry-
onic stage. At early stages, symmetrical cell division occurs with
each stem cell giving rise to two daughter stem cells, a process that
is crucial to the accumulation of a sufﬁcient pool of stem cells to
provide the large number of neurons required for normal neuronal
development [93]. At a later stage, there is a switch to asymmetric
division, with each stem cell generating one daughter stem cell and
one progenitor cell, which will differentiate to become a neuron
[94]. The VZ-SVZ compartment can be readily distinguished from
the IZ region and the CP by position relative to the ventricle
and the ventricular membrane. Importantly, the VZ/SVZ cells
are exquisitely sensitive to apoptosis; indeed apoptosis can be
activated in the VZ/SVZ by <0.5 Gy radiation whilst apoptosis is not
induced even by high doses (>10 Gy) in the adult brain [95]. Apo-
ptosis is also sensitively activated in the IZ compartment, although
less readily than in the VZ/SVZ [96]. Importantly, DNA ligase IV
null embryos die between E13.5 and E16.5 from massive neuronal
apoptosis, suggesting that endogenous DSBs may  arise from the
rapid cell division at this developmental stage [40,97]. Loss of p53
relieved both the neuronal apoptosis and embryonic cell death
conferred by loss of DNA ligase IV [97]. Studies on neurogenesis
using a mouse model for LigIV Syndrome (LigIVY288C) showed
small heads (as well as small bodies) and elevated apoptosis in the
VZ/SVZ and IZ compartments [95]. Although exposure of wild type
embryos to radiation resulted in a greater level of apoptosis in
the VZ/SVZ compared to the IZ, the level of endogenous apoptosis
in the LigIVY288C embryos was  greater in the IZ compartment.
Increased  levels of unrepaired DSBs correlated with the increased
endogenous apoptosis. Collectively, the analysis suggested that
two factors contribute to the marked impact of loss of DNA ligase
IV during neurogenesis. Firstly, the rapid replication from E8 to
E16.5 causes enhanced DSB formation, which require NHEJ for
repair. Secondly, there is a low threshold for activating apoptosis
in the VZ/SVZ and IZ such that apoptosis is activated by a smallDSBs most likely arise in other tissues due to diminished NHEJ
capacity, the impact appears greater in the embryonic neuronal
stem/progenitor cell compartment due to the exquisite sensitivity
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or activating apoptosis. As mentioned above, a surprising ﬁnding
as the enhanced level of apoptosis in the IZ compared to the
Z/SVZ compartment in LigIVY288C embryos. A potential explana-
ion is that diminished NHEJ capacity allows the persistence of
SBs; thus, cells harbouring DSBs may  progress from the VZ/SVZ
nto the IZ; in contrast, the induced DSBs in an irradiated wild type
ouse are likely to undergo rapid repair. Interestingly, the G2/M
amage-induced checkpoint in the embryonic brain is not acti-
ated by low numbers of DSBs, potentially allowing cells with DSBs
hat arise in the VZ/SVZ to progress into the IZ compartment [95].
As  mentioned above, Artemis-null patients do not display
icrocephaly and Artemis-null mice are developmentally normal
apart from a SCID phenotype). As discussed above, Artemis-
efective cells have a distinct DSB repair defective phenotype
ompared to that observed in LIG4 Syndrome cells or cells deﬁcient
n XLF: the Artemis defect results in a complete failure to repair a
5% subset of DSBs; deﬁciency in DNA ligase IV or XLF results in slow
epair of all DSBs (Fig. 7). It is possible that the number of unrepaired
SBs in the absence of Artemis in the VZ/SVZ compartment lies
elow the threshold required to activate apoptosis. Another possi-
ility is that the DSBs that arise from rapid replication are distinct to
adiation induced DSBs and do not require Artemis for their repair.
he current models propose that HR plays the major role in repair-
ng replication-associated DSBs; thus, a role for NHEJ is perhaps
urprising. It is, therefore, currently unclear whether the elevated
SBs observed in LigIVY2988C mice arise directly from replication-
ssociated DSBs or, for example, arise as a consequence of the high
etabolic rate in these cells.
As mentioned above NBS and RAD50-deﬁcient patients present
ith a similar microcephalic phenotype to LIG4 Syndrome patients
82]. However, NBS patient cells, like Artemis defective cells, have
 mild DSB repair defect. Although the precise role is still contro-
ersial, there is evidence that the MRN  complex is also involved
n promoting recovery from replication stalling. Details of the
asis underlying the microcephaly phenotype in NBS or RAD50-
eﬁciency is, therefore, likely to be somewhat distinct to LIG4
yndrome, although rapid replication and sensitive apoptotic acti-
ation most likely causally contribute to microcephaly in all the
isorders.
The markedly impaired pre and post-natal neuronal devel-
pment observed in one DNA-PKcs patient likely also arises as
 consequence of high apoptosis caused by persistent, unre-
aired DSBs during neurogenesis. It is possible also that uncapped
elomeres, which could arise if telomere length is not efﬁciently
aintained, could additionally signal to the apoptotic machinery.
he post natal impact is unlikely to be a consequence of sensitively
ctivated apoptosis but this has not been thoroughly examined.
Finally,  a diminished ability to generate neurons due to cell
oss leads to a diminished size of the cerebellum. This renders the
ppearance of a pronounced nose and underlies the dysmorphic
acial features also observed in LIG4 Syndrome and XLF-deﬁcient
atients, a feature also observed in Seckel Syndrome [98]. The
rowth delay observed in NHEJ-deﬁcient patients could be the
esult of a similar impact of unrepaired DSBs on cell loss (via
poptosis or merely a failure to replicate) in other stem cell com-
artments.
. How does our knowledge enhance patient care
RS-SCID patients can be identiﬁed by assessment of their cel-
ular radiosensitivity or their capacity to repair DSBs. Increasingly,
equencing of candidate genes is employed to identify patients. The
rovision of a diagnosis is normally psychologically beneﬁcial for
he patient or their family. However, there are additional beneﬁts
o providing a diagnosis.pair 17 (2014) 9–20 17
Currently, SCID can be readily treated by bone marrow trans-
plantation (BMT), which although costly has a high success rate.
However, previous studies have shown that RS-SCID patients and
particularly LIG4 Syndrome patients can over-react to the con-
ditioning regime employed to avoid a host-graft response [99].
Alternative regimes which avoid the use of DSB inducing agents
have been developed for such patients and found to be highly efﬁ-
cient [100]. The long term outcome for Artemis deﬁcient patients to
BMT  appears less positive than for other SCID conditions, and such
knowledge can enhance the treatment pre and post BMT  [65,101]
Thus, providing an RS-SCID diagnosis can allow the optimisation of
conditioning regimes as well as post transplantation care. Further,
there appears to be an elevated incidence of lymphoid leukaemias
in some of the RS-SCID patients. Thus, knowledge of a patient’s
genetic defect can be beneﬁcial in deciding if BMT  is the preferred
treatment and/or if radiotherapy can be exploited during treat-
ment. Indeed, the ﬁrst LIG4 Syndrome patient identiﬁed showed
a marked over-response to radiotherapy [44]. Although BMT  can
relieve the immunodeﬁciency of RS-SCID, all the non-immune
somatic cells will retain DSB repair defect and potentially enhanced
genomic instability. Such patients may  need close surveillance
for the onset of cancer. Although there is currently no evidence
that such patients respond abnormally to the low dose of radia-
tion employed during diagnostic X-ray exposures and computed
tomography (CT) scanning, there remains a strong possibility that
this could arise, with patients possibly enduring an enhanced like-
lihood of radiation-induced carcinogenesis. The beneﬁts versus
harmful effects of such exposures need to be carefully weighed
when caring for such patients. Finally, although the diagnosis of
LIG4 Syndrome, XLF-defects and null-Artemis patients is efﬁcient,
leaky Artemis deﬁciency is harder to identify; cellular radiosensi-
tivity without defective DSB repair or with cell cycle stage speciﬁc
DSB repair defects have been reported [67,72].
Given the beneﬁts of diagnosis, there is scope for enhancing the
diagnostic procedures. One approach is the screening of newborn
SCID patients using the T cell receptor excision circle (TREC) assay,
which detects an intermediate formed during V(D)J recombination
[102]. Another procedure has the potential to enhance diagnosis
of patients with mild or cell cycle-speciﬁc DSB repair defects by
enhancing the efﬁcacy of the current approach of analysis, which
involves the enumeration of H2AX foci [103]. In summary, the
diagnosis of RS-SCID patients has the potential to enhance their care
and treatment, and diagnostic procedures, particularly those allow-
ing the rapid identiﬁcation of hypomorphic Artemis CID patients,
need to be optimised.
8.  Concluding remarks
Although  the double helical structure of DNA suggested a stable
structure endowed with the capacity to maintain a cell’s genetic
information and transfer it to daughter cells, we now appreciate
that the DNA molecule incurs a substantial level of damage. Thus,
repair mechanisms are critical for maintaining the DNA stability.
The development of the immune response necessitates the gener-
ation of genetic diversity and exploits the DNA damage response
proteins. A substantial number of patients impaired in their abil-
ity to repair DSBs and consequently diminished in their capacity
to develop an immune response has now been identiﬁed. The fea-
tures of such patients have additionally revealed a signiﬁcant role
for the major DSB rejoining process, NHEJ, during neurogenesis. The
patients identiﬁed to date likely represent the extreme spectrum of
the impact of loss or deﬁciency of NHEJ proteins on human health.
It is likely that milder defects confer somewhat less dramatic but
distinct phenotypes, which could be substantially more common.
This is exempliﬁed by “leaky” Artemis deﬁcient patients, where
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rogressive immunodeﬁciency has been reported (Table 3). Now
hat we have signiﬁcant insight into this extreme end of the spec-
rum, further work is required to identify the clinical impact of less
mpacting mutational changes. Our insight has already enhanced
he care of RS-SCID patients but further work is required to optimise
heir diagnosis as well as their long term outcome.
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